Last reviewed · How we verify
VNRX-5133 and VNRX-5022 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
VNRX-5133 and VNRX-5022 (VNRX-5133 and VNRX-5022) — Venatorx Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| VNRX-5133 and VNRX-5022 TARGET | VNRX-5133 and VNRX-5022 | Venatorx Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- VNRX-5133 and VNRX-5022 CI watch — RSS
- VNRX-5133 and VNRX-5022 CI watch — Atom
- VNRX-5133 and VNRX-5022 CI watch — JSON
- VNRX-5133 and VNRX-5022 alone — RSS
Cite this brief
Drug Landscape (2026). VNRX-5133 and VNRX-5022 — Competitive Intelligence Brief. https://druglandscape.com/ci/vnrx-5133-and-vnrx-5022. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab